The Dual Role of PAI-1 Mutations in Bleeding and Thrombotic Disorders – ICHCC
Iranian Comprehensive Hemophilia Care Center (ICHCC) shared a post on LinkedIn:
“PAI-1 Mutation versus PAI-1 Deficiency — Clinical Differences:
Plasminogen Activator Inhibitor-1 (PAI-1) is a key regulator of the fibrinolytic system and controls the activity of tPA and uPA.
Although the terms PAI-1 mutation and PAI-1 deficiency are sometimes used interchangeably, they can present very differently clinically.
What is PAI-1 Deficiency?
PAI-1 deficiency is a rare inherited bleeding disorder caused by markedly reduced or absent PAI-1 activity.
Main Clinical Features:
- Delayed bleeding after trauma or surgery
- Menorrhagia
- Epistaxis
- Postpartum hemorrhage
- Excessive fibrinolysis with unstable clot formation
Patients usually have normal coagulation tests but increased fibrinolytic activity.
What does ‘PAI-1 mutation’ mean?
A PAI-1 mutation may lead to:
- low function (loss-of-function)
- high expression/activity (gain-of-function)
- altered regulation of fibrinolysis
Therefore, not all PAI-1 mutations cause bleeding.
Clinical Difference
PAI-1 Deficiency usually presents with:
- Bleeding tendency
- Hyperfibrinolysis
- Poor clot stability
Certain PAI-1 Mutations May instead be associated with:
- Thrombotic tendency
- Increased fibrosis
- Cardiovascular risk
- Metabolic syndrome (in some polymorphisms)
Example:
The 4G/5G polymorphism can influence PAI-1 expression and thrombosis risk.
Key Concept
PAI-1 deficiency equals absence/reduction of inhibitor – excessive fibrinolysis – bleeding
Some PAI-1 mutations equals excess inhibitor activity – impaired fibrinolysis – thrombosis
Take-home Message
Not every PAI-1 mutation behaves like true PAI-1 deficiency.
The clinical presentation depends on whether the mutation decreases or increases PAI-1.”

Stay updated with Hemostasis Today.
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation
-
Jul 13, 2026, 22:33ESOC 2026 recordings are now available on eSTEP – European Stroke Organisation
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026